Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MYC | P01106 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 5/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | SPR | P35270 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10330247 | 0.84 | HPGD (0.56) | SMN1; SMN2ALDH1A1RAB9AMAPTHRH3 | |
| SCHEMBL12442637 | 0.83 | HPGD (0.62) | SMN1; SMN2ALDH1A1RAB9AMAPTHRH3 | |
| SCHEMBL29944223 | 0.83 | HPGD (0.62) | SMN1; SMN2ALDH1A1RAB9AMAPTHRH3 | |
| SCHEMBL1722269 | 0.82 | SMN1; SMN2 (0.59) | SMN1; SMN2ALDH1A1RAB9AMAPTHRH3 | |
| SCHEMBL13779974 | 0.81 | ALDH1A1 (0.51) | SMN1; SMN2ALDH1A1RAB9AMAPTHRH3 | |
| SCHEMBL7877444 | 0.81 | SMN1; SMN2 (0.70) | SMN1; SMN2ALDH1A1RAB9AMAPTNPC1 | |
| SCHEMBL2733860 | 0.80 | ALDH1A1 (0.47) | ALDH1A1MAPTMYCHPGD | |
| SCHEMBL27531647 | 0.80 | ALDH1A1 (0.47) | SMN1; SMN2ALDH1A1RAB9AMAPTHRH3 | |
| SCHEMBL18390537 | 0.78 | HRH3 (0.62) | ALDH1A1HRH3MYCHPGD | |
| SCHEMBL14872321 | 0.78 | RAB9A (0.50) | SMN1; SMN2ALDH1A1RAB9ANPC1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070079392-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2007-04-05 | — | — | US | claimed |
| US-20050004178-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | US | claimed |
| US-20040142377-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2004-07-22 | — | — | US | claimed |
| EP-3042900-B1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORP (JP) | 2020-09-23 | — | — | EP | disclosed |
| US-9586951-B2 | Morpholine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| US-9586951-B2 | Morpholine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| US-9586951-B2 | Morpholine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| EP-3042900-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | Fujifilm Corporation (JP) | 2016-07-13 | — | — | EP | disclosed |
| EP-3042900-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | Fujifilm Corporation (JP) | 2016-07-13 | — | — | EP | disclosed |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2016-06-16 | — | — | US | disclosed |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2016-06-16 | — | — | US | disclosed |
| US-7829298-B2 | Human G protein-coupled receptors for metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20080139628-A1 | Compositions For Treating Flushing And Lipid-Associated Disorders Comprising Niacin Receptor Partial Agonists | ARENA PHARMACEUTICALS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| EP-1811996-A1 | COMPOSITIONS FOR TREATING FLUSHING AND LIPID-ASSOCIATED DISORDERS COMPRISING NIACIN RECEPTOR PARTIAL AGONISTS | Arena Pharmaceuticals, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20070079392-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2006052569-A1 | COMPOSITIONS FOR TREATING FLUSHING AND LIPID-ASSOCIATED DISORDERS COMPRISING NIACIN RECEPTOR PARTIAL AGONISTS | ARENA PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20050154029-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2005-07-14 | — | — | US | disclosed |
| US-6902902-B2 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2005-06-07 | — | — | US | disclosed |
| US-20050004178-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | US | disclosed |
| US-20040142377-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154029-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | GPR119, ADIPOR2, GCGR | SMN1; SMN2 1613/4885ALDH1A1 2465/4885RAB9A 1862/4885 |
| US-20070079392-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | GPR119, ADIPOR2, GCGR | SMN1; SMN2 1613/4885ALDH1A1 2465/4885RAB9A 1862/4885 |
| US-20080139628-A1 | Compositions For Treating Flushing And Lipid-Associated Disorders Comprising Niacin Receptor Partial Agonists | FFAR1, FFAR2, FFAR3 | SMN1; SMN2 4460/4885ALDH1A1 1861/4885RAB9A 2083/4885 |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | PRMT7, RBBP7, RER1 | SMN1; SMN2 1734/4885ALDH1A1 2519/4885RAB9A 757/4885 |
| US-20050004178-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | GPR119, ADIPOR2, GCGR | SMN1; SMN2 1613/4885ALDH1A1 2465/4885RAB9A 1862/4885 |
| US-20040142377-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | GPR119, ADIPOR2, GCGR | SMN1; SMN2 1613/4885ALDH1A1 2465/4885RAB9A 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.